PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker-driven clinical phase II AIO study

PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker-driven clinical phase II AIO study

Combination chemotherapy has shown benefit in the treatment of biliary cancer and further improvements might be achieved by the addition of a biological agent. We report here the effect of chemotherapy with the monoclonal EGFR antibody panitumumab as therapy for KRAS wild-type biliary cancer. Patien...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) Vol. 92; pp. 11 - 19
Main Authors: Vogel, Arndt, Kasper, Stefan, Bitzer, Michael, Block, Andreas, Sinn, Marianne, Schulze-Bergkamen, Henning, Moehler, Markus, Pfarr, Nicole, Endris, Volker, Goeppert, Benjamin, Merx, Kirsten, Schnoy, Elisabeth, Siveke, Jens T., Michl, Patrick, Waldschmidt, Dirk, Kuhlmann, Jan, Geissler, Michael, Kahl, Christoph, Evenkamp, Ralph, Schmidt, Torben, Kuhlmann, Alexander, Weichert, Wilko, Kubicka, Stefan
Format: Journal Article
Language:English
Published: England Elsevier Ltd 01-03-2018
Elsevier Science Ltd
Subjects:
Antibodies
Bilary cancer
Biliary tract
Biomarkers
Cancer
Chemotherapy
Cisplatin
Clerical studies
Clinical trials
EGFR
Epidermal growth factor receptors
Gemcitabine
Genetic profiling
Immunotherapy
K-Ras protein
KRAS
Monoclonal antibodies
p53 Protein
Panitumumab
Patients
Randomization
Reagents
Survival
Targeted cancer therapy
Toxicity
Bilary cancer
Genetic profiling
Chemotherapy
KRAS
Panitumumab
EGFR
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Combination chemotherapy has shown benefit in the treatment of biliary cancer and further improvements might be achieved by the addition of a biological agent. We report here the effect of chemotherapy with the monoclonal EGFR antibody panitumumab as therapy for KRAS wild-type biliary cancer. Patients with advanced biliary tract cancer were randomised (2:1) to receive cisplatin 25 mg/m2 and gemcitabine 1000 mg/m2 on day 1 and day 8/q3w with (arm A) or without panitumumab (arm B; 9 mg/kg BW, i.v q3w). The primary end-point was the evaluation of progression-free survival (PFS) at 6 months. Secondary end-points included objective response rate (ORR), overall survival (OS), and toxicity. In addition, a post hoc assessment of genetic alterations was performed. Finally, we performed a meta-analysis of trials with chemotherapy with and without EGFR antibodies. Sixty-two patients were randomised in arm A and 28 patients in arm B. Patients received 7 treatment cycles in median (1–35) with a median treatment duration of 4.7 months (141 days, 8–765). PFS rate at 6 months was 54% in patients treated with cisplatin/gemcitabine and panitumumab but was 73% in patients treated with cisplatin/gemcitabine without antibody, respectively. Secondary end-points were an ORR of 45% in treatment arm A compared with 39% receiving treatment B and a median OS of 12.8 months (arm A) and of 20.1 months (arm B), respectively. In contrast to the p53-status, genetic alterations in IDH1/2 were linked to a high response after chemotherapy and prolonged survival. In accordance with our results, the meta-analysis of 12 trials did not reveal a survival advantage for patients treated with EGFR antibodies compared with chemotherapy alone. Panitumumab in combination with chemotherapy does not improve ORR, PFS and OS in patients with KRAS wild-type, advanced biliary cancer. Genetic profiling should be included in CCA trials to identify and validate predictive and prognostic biomarkers. The trial was registered with NCT01320254. •Panitumumab was evaluated in KRAS wild-type patients with biliary cancer.•Addition of EGFR antibody to standard chemotherapy does not improve outcome of patients.•Molecular profiling identified p53 and IDH1/2 mutation as most common genetic alteration in our patient population.•IDH1/2 mutations might predict benefit from platin-based chemotherapy, which should be explored in prospective trials.
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2017.12.028